CHA2DS2-VA and non-CHA2DS2-VA components as predictors of mortality after cavotricuspid isthmus ablation: a clinical tool for long-term risk stratification - Top-Institutions - MDSpire

Evaluating CHA2DS2-VA and Non-CHA2DS2-VA Factors as Indicators of Mortality Following Cavotricuspid Isthmus Ablation: A Tool for Long-Term Risk Assessment

  • By

  • Kamilla Luca Dávid

  • Előd János Zsigmond

  • Manuella Bogdan

  • Balázs Polgár

  • Nikolett Vigh

  • Zalán Gulyás

  • Judit Papp

  • Emese Tóth-Zsámboki

  • Gábor Zoltán Duray

  • July 20, 2026

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Cardiology
    • Electrophysiology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Cardiology
    • Electrophysiology

  • #3

    Sandwell and West Birmingham Hospitals NHS Trust
    Sandwell and West Birmingham Hospitals NHS Trust

    Birmingham, England

    Key Differentiators

    • Cardiology

  • #4

    University Hospital of Marburg
    University Hospital of Marburg

    Marburg, Germany

    Key Differentiators

    • Cardiology

  • #5

    Munich University Hospital, Ludwig-Maximilians-Universität
    Munich University Hospital, Ludwig-Maximilians-Universität

    Munich, Germany

    Key Differentiators

    • Cardiology

Original Source(s)

CHA2DS2-VA and non-CHA2DS2-VA components as predictors of mortality after cavotricuspid isthmus ablation: a clinical tool for long-term risk stratification

  • by Kamilla Luca Dávid, Előd János Zsigmond, Manuella Bogdan, Balázs Polgár, Nikolett Vigh, Zalán Gulyás, Judit Papp, Emese Tóth-Zsámboki, Gábor Zoltán Duray

  • July 20, 2026

Related Content

Early in-hospital initiation of angiotensin-receptor–neprilysin inhibitor in post-acute myocardial infarction patients with impaired left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials

Case Report: A rare stop-gained MYZAP mutation is associated with atrioventricular septal defects in an Arabian family

Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation